Xhance (fluticasone propionate) is a prescription nasal spray. It’s used to treat nasal and sinus inflammation with or without nasal polyps in adults. This drug can interact with other medications, ...
YARDLEY, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
LOS ANGELES (KABC) -- One in eight U.S. adults struggle to breathe and battle the persistent pain and discomfort of chronic sinusitis. Even with sprays, irrigations and pills, a staggering 80% of ...
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis patients without nasal polyps Clinical ...
YARDLEY, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Optinose (OPTN) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today ...
The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If ...
YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results